HUMA is trading 5.1% down at $0.73 as investors continue to digest recent dilution from a $60 million registered direct offering and a proposed public share sale.
- Sentiment is being shaped by split analyst views and valuation cuts following Humacyte’s vascular graft V012 data.
- A broader risk-off market tone today is adding additional downside pressure to the stock.